JaLCDOI 10.18926/AMO/31037
FullText URL fulltext.pdf
Author Takahashi, Isao| Inagaki, Noritoshi| Nakada, Hiroshi| Ohmoto, Eijiro| Takeuchi, Makoto| Osada, Ken| Matsuzaki, Toshiaki| Fukuda, Shunichi| Uchida, Kozaburo| Kohi, Fumikazu| Yorimitsu, Seiichi| Kimura, Ikuro| Kitajima, Koichi| Sanada, Hiroshi|
Abstract <p>Superoxide anion (O2-) production by neutrophils from 14 untreated patients with acute nonlymphocytic leukemia (ANLL) was significantly less than that of healthy controls (4.93 +/- 1.99 vx 6.20 +/- 1.53 nmol/min/10(6) neutrophils, p less than 0.05). In 10 patients with myelodysplastic syndrome (MDS), however, it was not significantly different from the control level although 6 of the 10 patients had low levels, when individual patients were compared with the lower limit of the control range. An inverse correlation between the O2- production of neutrophils and the percentage of leukemic cells in the marrow existed in ANLL (r = -0.55, p less than 0.01), but not in MDS. Three of 4 MDS patients who died of pneumonia prior to leukemic conversion showed a low level of O2- production. The impaired O2- production by neutrophils from some MDS patients, probably due to the faulty differentiation from leukemic clones, may be one of the causes of enhanced susceptibility to infection.</p>
Keywords superoxide anion production myelodysplastic syndrome preleukemia
Amo Type Article
Published Date 1988-02
Publication Title Acta Medica Okayama
Volume volume42
Issue issue1
Publisher Okayama University Medical School
Start Page 15
End Page 19
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 2834918
Web of Sience KeyUT A1988M237800003
JaLCDOI 10.18926/AMO/31015
FullText URL fulltext.pdf
Author Takahashi, Isao| Sekito, Noriko| Takeuchi, Makoto| Osada, Ken| Matsuzaki, Toshiro| Fukuda, Shunichi| Lai, Minyu| Uchida, Kozaburo| Kimura, Ikuro| Miyamoto, Kanji| Kitajima, Koichi| Sanada, Hiroshi|
Abstract <p>The rearrangement of breakpoint cluster region (ber) was examined in leukemic cells obtained from 3 patients initially diagnosed as having Ph+ acute leukemia, 2 with acute lymphocytic leukemia (ALL) and one with acute mixed leukemia. DNA was digested with Bgl II and BamH I. The ber rearrangement was present in the case of acute mixed leukemia (Case 1), but was absent in the 2 cases of ALL (Cases 2 and 3). These results suggest that Case 1 represented a type of blast crisis of chronic myelocytic leukemia which was unusual in the sense of the occurrence of a myeloid-lymphoid conversion and lack of an apparent chronic phase. Cases 2 and 3 appeared to be de novo Ph+ ALL.</p>
Keywords Ph-positive acute leukemia blast crisis with a silent chronic phase myeloidlymphoid conversion chronic myelocytic leukemia bcr-rearrangement
Amo Type Article
Published Date 1988-04
Publication Title Acta Medica Okayama
Volume volume42
Issue issue2
Publisher Okayama University Medical School
Start Page 117
End Page 120
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 3164571
Web of Sience KeyUT A1988N237200008
JaLCDOI 10.18926/AMO/30705
FullText URL fulltext.pdf
Author Takahashi, Isao| Hara, Masamichi| Uchida, Kozaburo| Takaoka, Kazuko| Watanabe, Seiichiro| Lai, Minyu| Hamasaki, Kazuhide| Kohi, Fumikazu| Kitajima, Koichi| Kimura, Ikuro| Adachi, Tomiro| Yorimitsu, Seiichi| Tokioka, Masaaki| Sanada, Hiroshi|
Abstract <p>Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.</p>
Keywords aclarubicin cytosine arabinoside chemotherapy acute myelocytic leukemia
Amo Type Brief Note
Published Date 1982-02
Publication Title Acta Medica Okayama
Volume volume36
Issue issue1
Publisher Okayama University Medical School
Start Page 77
End Page 80
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 6950658
Web of Sience KeyUT A1982NE20000009